SEARCH

SEARCH BY CITATION

References

  • 1
    Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989; 312:10921099.
  • 2
    Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Am J Pathol 1990; 137:667676.
  • 3
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13:619626.
  • 4
    Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJM, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13:150157.
  • 5
    Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101:16491655
  • 6
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14:104111.
  • 7
    Harrison RF, Davies MH, Goldin RD, Hubscher SG. Recurrent hepatitis B in liver allografts: A distinctive form of rapidly developing cirrhosis. Histopathology 1993; 23:2128.
  • 8
    Lau JYN, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJM, Williams R. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102:956962.
  • 9
    Mason AL, Wick M, White HM, Benner KG, Lee RG, Regenstein F, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993; 105:237244.
  • 10
    Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A 1987; 84:69096913.
  • 11
    Roingeard P, Romet-Lemonne J-L, Leturcq D, Goudeau A, Essex M. Hepatitis B virus core antigen accumulation in an HBV nonproducer clone of HepG2-transfected cells is associated with cytopathic effect. Virology 1990; 179:113120.
  • 12
    Lau JYN, Bain VG, Smith HM, Alexander GJ, Williams R. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation 1992; 53:894898.
  • 13
    Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, Shafritz DA. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630633.
  • 14
    Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol 1995; 22:257262.
  • 15
    Belle SH, Beringer KC, Murphy JB, Detre KM. The Pitt-UNOS liver transplant registry. In: TerasakiPI, CeckaJM (eds). Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1992:1731.
  • 16
    Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H, Jr. Retransplantation in hepatitis B. A multicenter experience. Transplantation 1994; 57:823826.
  • 17
    National Institutes of Health Consensus Development Conference Statement: Liver transplantation—June 20–23, 1983. Hepatology 1984; 4(suppl):S107S110.
  • 18
    Van Thiel DH, Schade RR, Gavaler JS, Shaw BW Jr, Iwatsuki S, Starzl TE. Medical aspects of liver transplantation. Hepatology 1984; 4(suppl):S79S83.
  • 19
    Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19:40514053.
  • 20
    Lake JR. Liver transplantation for patients with hepatitis B: What have we learned from our results? Hepatology 1991; 13:796799.
  • 21
    Perrillo RP, Mason AL. Hepatitis B and liver transplantation. Problems and promises. N Engl J Med 1993; 329:18851887.
  • 22
    Johnson PJ, Wansbrough-Jones MH, Portmann B, Eddleston ALW, Williams R. Familial HBsAg-positive hepatoma: Treatment with orthotopic liver transplantation and specific immunoglobulin. BMJ 1978; 1:278.
  • 23
    Rizzetto M, Macagno S, Chiaberge E, Verme G, Negro F, Marinucci G, et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 2:469471.
  • 24
    Lauchart W, Muller R, Pichlmayr R. Immunoprophylaxis of hepatitis B reinfection in recipients of human liver allografts. Transplant Proc 1987; 19:23872389.
  • 25
    Colledan M, Grendele M, Gridelli B, Rossi G, Fassati LR, Ferla G, et al. Long-term results after liver transplantation in B and delta hepatitis. Transplant Proc 1989; 21:24212423.
  • 26
    Starzl TE, Todo S, Tzakis A, Gordon RD, Makowka L, Stieber A, et al. Liver transplantation: An unfinished product. Transplant Proc 1989; 21:21972200.
  • 27
    McMahon G, Ehrlich PH, Moustafa ZA, McCarthy LA, Dottavio D, Tolpin MD, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15:757766.
  • 28
    Muller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, et al. Liver transplantation in HBs antigen carriers. Prevention of hepatitis B virus recurrence by passive immunization. J Hepatol 1991; 13:9096.
  • 29
    Samuel D, Bismuth A, Mathieu D, Arulnaden J-L, Reynes M, Benhamou J-P, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337:813815.
  • 30
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, Bismuth H, and the Investigators of the European Concerted Action on Viral Hepatitis Study. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847.
  • 31
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32:11891195.
  • 32
    Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994; 21:204210.
  • 33
    Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: Insights into management. Liver Transpl Surg 1995; 1:8999.
  • 34
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:13581364.
  • 35
    Villamil FG, Kuhns MC, McNamara AL, Wolf GM, Hoffman AL, Makowka L, Vierling JM. Recurrent hepatitis B virus infection in patients receiving hepatitis B immunoglobulin after liver transplantation: Predictive value of circulating HBV DNA by polymerase chain reaction [abstract]. Hepatology 1994; 20:129A.
  • 36
    Feray C, Zignego L, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49:11551158.
  • 37
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24:13271333.
  • 38
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213222.
  • 39
    Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde K-H, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254263.
  • 40
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496501.
  • 41
    Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35:176181.
  • 42
    Ishitani M, McGory R, Dickson R, Caldwell S, Bickston S, McCollough C, et al. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 1997; 64:410414.
  • 43
    Marcellin P, Samuel D, Areias J, Loriot M-A, Arulnaden J-L, Gigou M, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19:612.
  • 44
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:12121215.
  • 45
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585589.
  • 46
    Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5:491496.
  • 47
    Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5:520525.
  • 48
    Villeneuve J-P, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207210.
  • 49
    Lo C-H, Cheung S-T, Lai C-L, Liu C-L, Oi-Lin I, Yuen M-F, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233:276281.
  • 50
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424432.
  • 51
    Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B virus infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001; 34:411416.
  • 52
    Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72:13811385.
  • 53
    Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433439.
  • 54
    Locarnini SA. Hepatitis B surface antigen and polymerase gene variants: Potential virological and clinical significance. Hepatology 1998; 27:294297.
  • 55
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134.
  • 56
    Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30:715721.
  • 57
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107113.
  • 58
    Dodson F, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6:434439.
  • 59
    Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomised trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888894.
  • 60
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan C-K, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody–positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 6:513517.
  • 61
    Terrault NA, Combs Holland C, Ferrell L, Hahn JA, Lake JR, Roberts JP, et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996; 2:132138.
  • 62
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713.
  • 63
    Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for hepatitis B after liver transplantation. J Hepatol 1998; 29:985989.
  • 64
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low doses of hepatitis B immune globulin. Liver Transpl Surg 1999; 5:512519.
  • 65
    Perrillo R, Rakela J, Dienstag J, Levy G, Martín P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:15811586.
  • 66
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113117.
  • 67
    Fontana RJ, Hann H-WL, Wright T, Everson G, Baker A, Schiff ER, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7:504510.
  • 68
    Rayes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO, Neuhaus P. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71:96101.
  • 69
    Bock C-T, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264273.
  • 70
    Kruger M, Tillmann HL, Trautwein C, Bode U, Oldhafer K, Maschek H, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transpl Surg 1996; 2:253262.
  • 71
    Manns MP, Neuhaus P, Atkinson GF, Griffin KE, Barnass S, Vollmar J, et al. Famciclovir treatment of hepatitis B infection following liver transplantation: A long-term multicenter study. Transpl Infect Dis 2001; 3:1623.
  • 72
    Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49:436440.
  • 73
    Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, Pillay D. Acute liver failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir. Gut 2001; 49:860863.
  • 74
    Han S-HB, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6:741748.
  • 75
    Angus PW, McCaughan GW, Gane EJ, Crawford DHG, Harlet H, and the Australian Liver Transplant Study Group. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6:429433.
  • 76
    Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001:14:903910.
  • 77
    Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation—Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895902.
  • 78
    Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68:10581061.